Scagliotti et al. J Clin Oncol 2008. Pemetrexed 500 mg/m2 +. Cisplatin 75 mg/m2.

J Clin Oncol 2009; 27:6251–6266 3Scagliotti GV et al. J Clin Oncol 2008;26:3543

Apr 10, 2010 . Corresponding author: Giorgio Scagliotti, MD, Department of Clinical and . for

Adapted with permission from Scagliotti. J Clin Oncol. 2008;26:3543. Surv iv.

Clin Cancer Res 2009;15:7547-7552; Scagliotti GV, JCO 2008 CDDP + Alimta

JMDB OS curves by Histology JCO Scagliotti. Posted by Dr West on June 9, 2008 at

N=752. Pem. N=64. Response. 26.3%. 21.7%. 5.5%. TTP. 7.0 mo. 6.9 mo. 4.7 mo

Jul 20, 2008 . Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne .

Mar 25, 2011 . N = 1700 Patients , Power 80%. B12, folate, and dexamethasone given in both

Stage III. Cis/Gem vs Cis/Pemetrexed: Survival in Nonsquamous Carcinoma.

NEJM. 2002;346;92-8. Sandler A ,et al. NEJM. 2006;355:2542-50. I-PASS. JMDB

CES. Cis/Pem vs. Cis/Gem in Advanced NSCLC. U. N. IV. ER. STY O. F TO. R. IN.

Apr 2, 2011 . Hamilton, Ontario: BC Decker, Inc.; 2006:1185; Georgoulias. Lancet. 2001;357:

Jul 20, 2008 . published online ahead of print at www.jco.org on May 27, 2008. REFERENCES.

Reproduced with permission from Scagliotti GV et al. J Clin Oncol. 2008;26(21):

Scagliotti et al, J Clin Oncol 2008. Bevacizumab improves survival in combination

Scagliotti (JCO 2008). Non SCC. 10.3. 10.4. 5.1. 4.7. 28.2%*. NC. 0 %. 0 %. 2 %.

J Clin Oncol 2008, 26:3543-3551. PubMed Abstract | Publisher Full Text

Feb 1, 2011 . Scagliotti GV et al, JCO 2008 ; 6.) Pirker R. et al Lancet 2009 ; 7.) Sandler A et al,

mets. Vitamin B-12, folate, and dexamethasone given in both arms. Gemcitabine

Scagliotti GV, et al. J Clin Oncol. 2008;26:3543-3551. 3. Scagliotti GV, et al.

LINE PROSPECTIVE ANALYSIS OF. HISTOLOGY AND OS. Ciuleanu et al. J Clin

J Clin Oncol 2008; 26:3543- 3551. 4. Scagliotti G, Hanna N, Fossella F, et al. The

Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma,

Dec 1, 2008 . published online ahead of print at www.jco.org on October 20, 2008.

Mar 25, 2011 . 11. Overall Survival in Patients with. Nonsquamous Histology. Scagliotti. JCO.

Differential effect of pemetrexed in non-squamous vs squamous cell carcinoma

Does Histology matter? Scagliotti GV, JCO 2008. Cisplatin (75mg/m2) d1. +

Pignon JP, Tribodet H, Scagliotti GV, et al., Lung adjuvant cisplatin evaluation: a

ECOG1594: Schiller N Engl J Med 2004. 2. TAX 326: Fossella JCO 2003. 3.

or PS. NSCLC Mata-Analyses Collaborative Group, JCO 2008 . Ann Intern Med

Scagliotti's study showing identical results for the 'average patient' (Scagliotti,

Pignon JP, Tribodet H, Scagliotti GV, et al., Lung adjuvant cisplatin evaluation: a

Dec 1, 2008 . 2008 American Society of Clinical Oncology. . Giorgio V. Scagliotti . published

taxanes (paclitaxel or docetaxel) were prior standard treatment. • The purpose of

J Clin Oncol 27(15s) (Abs# 7521) Scagliotti G, Pastorino U, . . Johnson EA,

ProcAm Soc Clin Oncol 2008:26 (abstract 3). 328. Cremonesi M, et al. Oncology

Le Chevalier et al, J Clin Oncol 1994; Argiris et al, Invest New Drugs 2006;.

Scagliotti GV. The ALPI Trial: the Italian/European experience with adjuvant .

1. Ceppi et al. 2006. Cancer 107:1589–96. 2. Ishihama et al. 2009. Jpn J Clin

Jul 20, 2008 . Jean-Pierre Pignon, Hélène Tribodet, Giorgio V. Scagliotti, Jean-Yves .

J Clin Oncol 29: 2011 (suppl; abstr e16639) . of phase 3 data in Sept 2007 (

Vitamin B12, folate, and dexamethasone given in both arms. Each cycle repeated

Nov 4, 2011 . N = 1700 Patients , Power 80%. B12, folate, and dexamethasone given in both

for advanced non-small cell lung cancer (NSCLC) (Scagliotti et al, J Clin Oncol.

Pemetrexed. 500 mg/m². D 1. ▪ Cisplatin. 75 mg/m². D 1. ▪ Adenocarcinoma. +

May 27, 2008 . J Clin Oncol. . Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J,

One study (N = 1725) tested cisplatin plus P versus cisplatin plus gemcitabine in

Brain mets hx. * Scagliotti, et al. J Clin Oncol 2008;26:3543–3551 . . quality of

Mar 7, 2009 . standard or ERCC1-customized cisplatin/docetaxel (Fossella et al. JCO. 2003:

Sitemap